Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Endometrial Neoplasms 8Ovarian Neoplasms 7Fallopian Tube Neoplasms 4Recurrence 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Neoplasms 2Breast Neoplasms 2Phase IB 1Multiple Myeloma 1Lung Neoplasms 1Endometrial Hyperplasia 1Colonic Neoplasms 1Carcinoma, Ovarian Epithelial 1Advanced, Persistent, or Recurrent Endometrial Cancer 1

Interventions

Paclitaxel 13pembrolizumab 8Carboplatin 7Surveys and Questionnaires 6Cisplatin 6Brachytherapy 5Doxorubicin 4Docetaxel 4Pemetrexed 3Hyperthermic Intraperitoneal Chemotherapy 3Gemcitabine 3FANG vaccine 3Biopsy 3osimertinib 2olaparib 2niraparib 2durvalumab 2adavosertib 2Trastuzumab 2Topotecan 2Taxes 2Standard of Care 2Sentinel Lymph Node Biopsy 2Saline Solution 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Oxaliplatin 2Nivolumab 2Music Therapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Uterine Neoplasms × Everolimus × Gynecologic × Clear all
NCT00087685 2025-05-01

RAD001 in Recurrent Endometrial Cancer Patients

M.D. Anderson Cancer Center

Phase 2 Completed
35 enrolled 6 charts
Gynecologic

Uterine Neoplasms, Endometrial Neoplasms

NCT03285802 2020-02-05

Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation

Greater Baltimore Medical Center

Phase 2/3 Completed
1 enrolled
Gynecologic

Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡